Sage Journals: Discover world-class research

Abstract

Using 1998 data for 8 transplantation centers located in New York City, this study found that kidney transplantation was a more cost-effective treatment than hemodialysis for the Medicare program. The initially higher costs of transplantation were fully recouped by Medicare 2 years and 10 months after surgery. For persons who are eligible for Medicare solely due to their end-stage renal disease status, transplantation would generate average monthly savings of $3800 over dialysis for the 2 years following the break-even point. For those eligible for reasons other than end-stage renal disease, for example, the aged, the average savings would be $2400. The savings difference arises because Medicare coverage for immunosuppressants for the former group ends 36 months after transplantation.

Get full access to this article

View all access options for this article.

References

United Network for Organ Sharing. UNOS critical data: Number of U.S. transplants by organ and donor type. Available at: http://www.unos.org/Newsroom/critdata_transplants_ustx.htm. Accessed May 30, 2000.

Merion

White

DJG

Thiru

Evans

Caline

. Cyclosporine: 5 years experience in cadaveric transplantation. N Engl J Med. 1984;310:148–154.

Ortho Multicenter Transplant Study Group. A Randomized Clinical Trial of OKT3 Monoclonal Antibody for acute rejection of cadaveric renal transplants. N Engl J Med. 1985; 313:337–342.

Sollinger

. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation. 1995;60:225–232.

Pirsch

Miller

Deierhoi

Vincenti

Filo

. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation. 1997;63:977–983.

HCFA announces new steps for racial equality in kidney transplantation [press release]. Washington, DC: HHS News; November 24, 1999.

United States Printing Government Office. Federal Register. Final Regulations. August 5, 1999;64(150):42765–42789. Available at: http://www.access.gpo.gov/su_docs/aces/aces140.html. Accessed December 5, 2000.

United States Renal Data System. USRDS 2000 Annual Report. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2000: Table B1, Table F3.

Forum of End Stage Renal Disease Networks. ESRD Program Highlights, 1984–1998

10.

United Network for Organ Sharing. UNOS critical data: Patients on the UNOS national patient waiting list. Available at: http://www.unos.org/Frame_default.asp?Category=Newsdata. Accessed December 2, 2000.

11.

United States Renal Data System. 2000 USRDS Annual Data Report Reference, Tables F.36 and F.38. Available at: http://www.usrds.org/reference.htm. Accessed December 5, 2000.

12.

Transplant shortages. New York Times. February 1, 1999; Editorial:A22.

13.

United States Renal Data System [database online]. Minneapolis, Minn: USRDS Coordinating Center; 2001. Updated July 31, 2001.

14.

Laupacis

Keown

Pus

. A study of the quality of life and cost-utility of renal transplantation. Kidney Int. 1996;50:235–242.

15.

Lawrence

Hunsicker

. A survival advantage for renal transplantation [editorial]. N Engl J Med. 1999;341:1762–1763.

16.

Eggers

. Analyzing the cost effectiveness of kidney transplantation. In: Proceedings of the 19th National Meeting of the Public Health Conference on Records and Statistics. Washington, DC: US Department of Health and Human Services; 1984:216–219. DHHS publication (PHS) 84-1214.

17.

Aroesty

Rettig

. The Cost Effects of Improved Kidney Transplantation. Santa Monica, Calif: Rand Corporation; 1984. Publication R-3099-NIH/RC.

18.

Eggers

. Comparison of treatment costs between dialysis and transplantation. Semin Nephrol. 1992;12:284.

19.

Schweitzer

Wiland

Evans

. The shrinking renal replacement therapy “break–even” point. Transplantation. 1998;66:1702–1708.

20.

Eggers

Kucken

. Cost issues in transplantation. Surg Clin North Am. 1994;14:1259–1267.

21.

Hauboldt

. Cost Implications of Human Organ and Tissue Transplantation, 1999. Milliman & Robertson, Inc. Available at: http://www2.milliman.com/milliman/publications/reports/Hrr16/default.html. Accessed October 31, 2000.

22.

Health Care Financing Administration. Provider Specific File. Available at: http://www.hcfa.gov/stats/pufiles.htm/pspecp99.exe. Accessed July 5, 1998.

23.

United States Renal Data System. 2000 USRDS annual data report reference tables G.12 and G.18. Available at: http://www.usrds.org/reference.htm. Accessed December 5, 2000.

24.

United Network for Organ Sharing. UNOS transplant data source center data. Available at: http://www.patients.unos.org/tpd/frm_stats_application.asp?org=KI&tab1=stat&tab2=esrd&table=0&bty=esrd&bval=2&ctr=&loc=MID. Accessed December 2, 2000.

25.

United States Renal Data System. 2000 Atlas of ESRD in the United States: Table K4. Available at: http://www.usrds.org/atlas.htm. Accessed December 5, 2000.

26.

Agency for Healthcare Research and Quality. HCUP Nation wide Inpatient Sample (NIS), 1997. Available at http://www.ahrq.gov/data/hcup/hcupnet.htm. Accessed February 2, 2001.

27.

Smith

Woodward

Cohen

. Cadeveric versus living donor kidney transplantation. Transplantation. 2000;69:311–314.

28.

FDA advisory panel backs new kidney transplant drug. Medical Industry Today [newsletter online]. July 29, 1999.

29.

Reikes

. Trends in end-stage renal disease. Post Graduate Medicine. 2000;108:124–144.

The Economics of Kidney Transplantation versus Hemodialysis

Abstract

Get full access to this article

References